Clinical Outcomes of Patients Receiving Stereotactic Body Radiotherapy Dose De-escalation for Hepatocellular Carcinoma at the Hepatic Hilum
Dose de-escalation SBRT for centrally located HCC showed good local control with no grade 3 or more RT related toxicities, suggesting it may be a safe alternative.
Authors
- Masafumi Ikeda (ORCID: https://orcid.org/0000-0002-4050-2086)
- Hidenari Hirata (ORCID: https://orcid.org/0000-0003-3130-6857)
- S. Zenda
- Kenji Makita (ORCID: https://orcid.org/0000-0002-2219-6708)
- Hidekazu Oyoshi (ORCID: https://orcid.org/0000-0002-5600-0312)
- Masaki Nakamura (ORCID: https://orcid.org/0000-0002-4431-8892)
- Kento Tomizawa (ORCID: https://orcid.org/0000-0002-7822-2952)
- Takeshi Fujisawa (ORCID: https://orcid.org/0009-0006-4426-7147)
- Hidehiro Hojo (ORCID: https://orcid.org/0000-0001-5278-1070)
- Yuzheng Zhou (ORCID: https://orcid.org/0000-0003-3804-6752)
- K. Fukushi
Institutions
- Shikoku Cancer Center (JP)
- National Cancer Center Hospital East (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2025-03-01
- DOI
- https://doi.org/10.21873/anticanres.17503
- Citations
- 1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.32